Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss drug retatrutide shows promise in phase 3 trial

NCT ID NCT07357415

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing different ways to increase the dose of retatrutide, a new weight-loss drug, in 600 people with obesity or overweight who do not have type 2 diabetes. The study lasts about 113 weeks and measures weight loss, waist size, and other health markers. The goal is to find the safest and most effective dosing schedule.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Retatrutide (a drug injected under the skin)
What this could lead to
If successful, this could lead to a more effective weight-loss treatment for people with obesity or overweight, potentially reducing related health risks like high blood pressure and heart disease.
What could go wrong
This is an early-stage phase 3 trial, so results are not yet confirmed. The drug may cause side effects, and weight loss may vary. It is not a cure for obesity, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a Body Mass Index (BMI) at screening * ≥ 30 kilogram per square meter (kg/m2) OR * ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * heart attack * stroke * hospitalization for unstable angina or heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Advanced Research Institute

    Ogden, Utah, 84405, United States

  • Aggarwal and Associates Limited

    Brampton, L6T 0G1, Canada

  • Arizona Research Center

    Phoenix, Arizona, 85053, United States

  • Brigham and Women's Hospital Diabetes Program

    Boston, Massachusetts, 02115, United States

  • C.I.C. Mauricie inc.

    Trois-Rivières, G8T 7A1, Canada

  • CAMC Institute for Academic Medicine

    Charleston, West Virginia, 25304, United States

  • CARDIAMET Investigaciones Médicas

    Buenos Aires, C1014ACP, Argentina

  • Canadian Phase Onward

    Toronto, M3J 0K2, Canada

  • Care Access - Huntington Beach

    Huntington Beach, California, 92648, United States

  • Care Access - Raleigh

    Raleigh, North Carolina, 27607, United States

  • Cedar Health Research

    Dallas, Texas, 75251, United States

  • Cedar Health Research - Fort Worth

    Fort Worth, Texas, 76132, United States

  • Cedar Health Research - Texas Native Health

    Dallas, Texas, 75235, United States

  • Centro Médico Viamonte

    Buenos Aires, C1120AAC, Argentina

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, C1056ABI, Argentina

  • Cicemo Srl

    Buenos Aires, 1424, Argentina

  • Diex Recherche Inc. Division Joliette

    Joliette, J6E 6A9, Canada

  • Diex Recherche Inc. Division Quebec

    Québec, G1V 4T3, Canada

  • Diex Recherche Inc. Division Sherbrooke

    Sherbrooke, J1L 0H8, Canada

  • Dominion Medical Associates, Inc.

    Richmond, Virginia, 23219, United States

  • Dr. Anil K. Gupta Medicine Professional Corporation

    Toronto, M9V 4B4, Canada

  • Encore Medical Research - Weston

    Weston, Florida, 33331, United States

  • Great Lakes Research Group, Inc.

    Bay City, Michigan, 48706, United States

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California, 90015, United States

  • Med Trust Research

    Courtice, L1E 2J5, Canada

  • Milestone Research Inc.

    London, N5W 6A2, Canada

  • Monroe Biomedical Research - Louisville

    Louisville, Kentucky, 40213, United States

  • NYC Research INC

    Long Island City, New York, 11106, United States

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • New Phase Research and Development

    Knoxville, Tennessee, 37909, United States

  • Pacific Diabetes & Endocrine Center

    Honolulu, Hawaii, 96817, United States

  • Stat Research S.A.

    Buenos Aires, C1023AAB, Argentina

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Weill Cornell Medical College

    New York, New York, 10021, United States

  • Winterberry Research Inc.

    Hamilton, L8J 0B6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.